Merck sets 2027 FDA action date for IDVYNSO HIV applications and will present data at HIV Glasgow 2026
Merck announced that the FDA has accepted two supplemental New Drug Applications for its once‑daily HIV regimen IDVYNSO and assigned a target action date of 22 April 2027. The company will showcase new treatment and prevention data, including Phase 3 results for IDVYNSO and investigational weekly and monthly oral regimens, at the HIV Glasgow conference from 8‑11 Nov 2026 in Scotland. Dr. Luisa Stamm, associate vice‑president and head of the HIV section at Merck Research Laboratories, said the presentations reflect the breadth of the company's HIV research. The conference will also feature policy and medical symposia on HIV elimination and individualized care.
Why it matters
The FDA action date determines when Merck could receive approval for expanded indications of IDVYNSO, potentially increasing its market share in the HIV treatment space. Investors should watch the upcoming conference for efficacy and safety data that may influence the likelihood of regulatory approval and future sales forecasts.
Key facts
- 1The FDA set a PDUFA target action date of 22 April 2027 for two supplemental applications for IDVYNSO. merck.com
- 2Merck will present new HIV treatment and prevention data at HIV Glasgow 2026, held 8–11 Nov 2026 in Glasgow, Scotland. merck.com
- 3Presentations will include Phase 3 subgroup analyses of IDVYNSO, weekly safety and efficacy data for investigational once‑weekly islatravir/lenacapavir, and enrollment completion for the once‑monthly PrEP candidate alimatravir. merck.com
- 4Dr. Luisa Stamm, associate vice‑president and head of the HIV section at Merck Research Laboratories, commented on the company's strategy to expand oral HIV options. merck.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.